Literature DB >> 21603910

Intravitreal anti-VEGF therapy with prompt or deferred laser compared with steroid with prompt laser and prompt laser alone for treatment of diabetic macular edema.

Jennifer K Sun1.   

Abstract

Entities:  

Year:  2011        PMID： 21603910     DOI： 10.1007/s11892-011-0201-3

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN： 1534-4827            Impact factor:   4.810


× No keyword cloud information.
  6 in total

1.  Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals.

Authors:  Anthony P Adamis; Michael Altaweel; Neil M Bressler; Emmett T Cunningham; Matthew D Davis; Mauro Goldbaum; Christine Gonzales; David R Guyer; Katz Barrett; Manju Patel
Journal:  Ophthalmology       Date:  2005-12-15       Impact factor: 12.079

2.  Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.

Authors:  Michael J Elman; Neil M Bressler; Haijing Qin; Roy W Beck; Frederick L Ferris; Scott M Friedman; Adam R Glassman; Ingrid U Scott; Cynthia R Stockdale; Jennifer K Sun
Journal:  Ophthalmology       Date:  2011-04       Impact factor: 12.079

3.  Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial.

Authors:  Florian K P Sutter; Judy M Simpson; Mark C Gillies
Journal:  Ophthalmology       Date:  2004-11       Impact factor: 12.079

4.  Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

Authors: 
Journal:  BMJ       Date:  1994-01-08

5.  Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1985-12

6.  Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study.

Authors:  Quan Dong Nguyen; Syed Mahmood Shah; Jeffery S Heier; Diana V Do; Jennifer Lim; David Boyer; Prema Abraham; Peter A Campochiaro
Journal:  Ophthalmology       Date:  2009-08-22       Impact factor: 12.079
  6 in total
  2 in total

1.  The Fundus Structural and Functional Predictions of DME Patients After Anti-VEGF Treatments.

Authors:  Hang Xie; Shihao Huang; Qingliang Liu; Yifan Xiang; Fabao Xu; Xiaoyan Li; Chun-Hung Chiu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-29       Impact factor: 6.055

2.  Transition from Laser to Intravitreal Injections for Diabetic Retinopathy: Hospital Utilization and Costs from an Extended Healthcare Perspective.

Authors:  Silvia Nanjala Walekhwa Hertzberg; Øystein K Jørstad; Beáta Éva Petrovski; Ragnheidur Bragadottir; Leif Arthur Steffensen; Morten Carstens Moe; Emily A Burger; Goran Petrovski
Journal:  Int J Environ Res Public Health       Date:  2022-10-02       Impact factor: 4.614
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.